Optimizing
the treatment of Parkinson’s disease
Read more
Improved
* As demonstrated in Phase III clinical study motor symptoms and daily function*
Read more
Good tolerability
* As demonstrated in Phase III clinical study and safety*
Read more
Once-daily capsule
no need for titration
Read more
P2B001 Completed
Phase 3 Study in Early PD
Read more

OUR COMPANY

We are striving to improve patients’ quality of life by developing innovative combination products, based on previously approved drugs, with favorable balance between safety and efficacy.

Read more >

WHAT IS P2B001?

P2B001 is a novel, once-daily combination of extended-release (ER) pramipexole, a low dose dopamine agonist (0.6mg), and rasagiline, a low dose MAO-B inhibitor (0.75mg), developed specifically for the treatment of..

Read more >

LATEST NEWS

OUR MISSION

We are striving to improve patients’ quality of life by developing innovative combination products, based on previously approved drugs,
with favorable balance between safety and efficacy.

.